UNSPSC 51191576: Furosemide sodium

This classification denotes a loop diuretic with the molecular formula C12H10CLN2O5S.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 101EM454S7. European Medicines Agency schedules furosemide sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02287MIG. Most nations, for tariff and trade purposes, schedule furosemide sodium under HS 29350090. As of Q4 2014, FUROSEMIDE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CC(OC1)CNC2CC(C(CC2C(=O)[O-])S(=O)(=O)N)CL.[NA+].

UNSPSC 51191576 Furosemide sodium is a Commodity code, but the recent state and local opportunities tagged under it show minimal alignment with the code's pharmaceutical scope. The City of Meriden's July 2026 solicitation (B027-15) seeks sodium bisulfite for water treatment at a municipal water pollution control facility—a chemical commodity unrelated to furosemide. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (S1070000015802), posted January 2026 with responses due March 26, 2026, targets generic multi-source pharmaceuticals and OTC products across state and local government facilities, which aligns more closely with the code's intended scope but casts a broad net across many pharmaceutical commodities rather than furosemide specifically. The mismatch between the code's narrow pharmaceutical focus and the actual work being solicited suggests either inconsistent state and local tagging practices or that furosemide-specific demand does not generate standalone solicitations in this market.

Geographic activity centers on Minnesota and Connecticut based on recent postings, with MMCAP coordinating multi-state pharmaceutical purchasing involving Oregon and other participating jurisdictions. The Meriden water-treatment bid represents municipal chemical procurement, while MMCAP's pharmaceutical RFP reflects state-level cooperative purchasing at a broader scale. The lack of dedicated furosemide solicitations and the presence of mistagged opportunities suggest this code does not reflect active, focused state and local demand. Firms targeting pharmaceutical supply to state and local health facilities should monitor MMCAP and comparable cooperative purchasing vehicles rather than expect narrowly scoped furosemide requests.